Merit Medical CEO Says OneMark Integration Is 'Slower Than I Would Like'
Martha Aronson said the Viewpoint acquisition has hit complications, though she kept her long-term view of the product intact.
Merit Medical Systems CEO Martha Aronson said on the company's third-quarter earnings call Thursday that the rollout of OneMark, the breast-localization product it gained through Viewpoint Medical, is "probably a little slower than I would like." The comment came on a call where Merit reported $416 million in revenue, up 8% from a year earlier.
Complications after the acquisition
Merit Medical, which makes catheters, guide wires, stents and other devices used in cardiology, radiology, oncology and endoscopy, said in prepared remarks that integration of Viewpoint "continues to progress." Asked by an analyst from Sidoti whether the first quarter with the business had gone as planned, Aronson was more candid.
She said "some aspects have gone a little slower than we had hoped," pointing to "a few more little complications." The team is moving manufacturing and bringing the product onto Merit's quality system, she said, and ScoutMD, the next-generation Scout device launched in late May, is landing in the same oncology sales force at the same time.
Earlier, an analyst from Piper Sandler asked whether Merit still felt good about its OneMark revenue targets for this year and next. Aronson answered that it was "still kind of early days to comment."
New accounts first, academic pipeline
Aronson said the sales team is aiming OneMark at new accounts rather than current Scout customers, since ScoutMD is rolling out to those. The pitch that surgeons can mark a lesion at biopsy, which may remove a separate localization procedure before surgery, is resonating, she said, with a strong pipeline of evaluations, particularly at academic institutions.
She said Merit remains "very excited" about OneMark's long-term opportunity. Together with ScoutMD, she said, it gives Merit a breast care offering spanning diagnosis, localization and surgery.
Oncology revenue rose about 16% in the quarter, Aronson said, helped by pent-up demand among customers upgrading to ScoutMD.
Strong quarter, raised guidance
Total organic constant-currency growth was 9%, and the adjusted operating margin rose to 21.3%. Merit now expects adjusted earnings of $4.33 to $4.37 a share for 2026, up from $4.25 to $4.35.
The company also said it paid about $45 million on October 13 to buy the rest of Solo Pace, maker of temporary pacing devices for heart-valve replacement procedures. Merit already held an 18% stake and distributed the systems.
Merit plans an investor event at its Salt Lake City headquarters on February 11, 2027, where it said it will present its strategic plan and new financial targets for 2027 through 2029.
Sources
- Merit Medical Systems Non-GAAP EPS of $1.12 beats by $0.08, revenue of $416.2M beats by $5.6M (MMSI:NASDAQ) | Seeking Alpha — seekingalpha.com
- Merit Medical Systems Q3 2026 Earnings Preview (MMSI:NASDAQ) | Seeking Alpha — seekingalpha.com
- Merit Medical Reports Third Quarter 2026 Results: Delivers — globenewswire.com
- Merit Medical Acquires Solo Pace, Inc., Expanding Its — globenewswire.com